Vertex Selects Two Next-Generation Correctors, VX-659 and VX-445, to Advance into Phase 3 Development as Part of Two Different Triple Combination Regimens for People with Cystic Fibrosis
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
| Vertex Pharmaceuticals Inc (NASDAQ: VRTX) | Delayed: 535.17 +10.65 (2.03%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $524.52 | 52 Week High | $134.71 | |||
| Open | $527.18 | 52 Week Low | $73.31 | |||
| Day High | $537.81 | P/E | N/A | |||
| Day Low | $521.30 | EPS | $-1.98 | |||
| Volume | 1,641,557 | |||||
